Literature DB >> 24726692

Usefulness of pH monitoring in predicting the survival status of patients with scleroderma awaiting lung transplantation.

Piero Marco Fisichella1, Nicholas P Reder2, James Gagermeier3, Elizabeth J Kovacs2.   

Abstract

BACKGROUND: Patients with scleroderma and end-stage lung disease (ESLD) have a very high prevalence of gastroesophageal reflux disease (GERD). Because GERD has been associated with aspiration in those with ESLD, and because those with scleroderma are particularly prone to develop severe GERD, there is some concern that GERD may contribute to shorten survival in patients with scleroderma awaiting lung transplantation. Therefore, we hypothesized that esophageal pH monitoring could predict survival of those with scleroderma and ESLD awaiting lung transplantation and that the severity of reflux can impact survival.
METHODS: We conducted a retrospective analysis of all scleroderma patients referred for lung transplantation who underwent esophageal manometry and pH monitoring since August 2008. We identified 10 patients in whom we calculated and compared the area under the curve for each receiver operating characteristic curve of the following variables: DeMeester score, forced expiratory volume in 1 s (FEV1), %predicted FEV1, forced vital capacity (FVC), %predicted FVC, diffusion capacity for carbon monoxide (DLco), and %predicted DLco.
RESULTS: The DeMeester score nominally outperformed FEV1, FVC, and DLco. Receiver operating characteristic curve analysis was also used to define the optimal DeMeester score (65.2) in differentiating survival status, as determined by maximizing sensitivity and specificity. Based on this value, we calculated the 1-y survival from the time of the esophageal function testing, which was 100% in seven patients with a DeMeester score of <65.2, and 33% in three patients with a score >65.2 (P = 0.01). The latter patients had greater total time pH < 4, greater time pH < 4 in the supine position, greater total episodes of reflux, and higher prevalence of absent peristalsis. The single survivor with a DeMeester score >70 had also proximal reflux, underwent antireflux surgery, and is alive 1201 d after transplant.
CONCLUSIONS: Our study shows that esophageal pH monitoring can predict survival status in patients with scleroderma awaiting lung transplantation and that the severity of reflux can impact the 1-y survival rate. Therefore, esophageal pH monitoring should be considered early in patients with scleroderma and ESLD, as this test could appropriately identify those in whom laparoscopic antireflux surgery should be performed quicker to prevent GERD and its detrimental effects in patients awaiting lung transplantation.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Connective tissue disorders; End-stage lung diseases; Esophageal pH monitoring; Gastroesophageal reflux disease; Laparoscopic antireflux surgery; Lung transplantation; Scleroderma

Mesh:

Year:  2014        PMID: 24726692      PMCID: PMC4316661          DOI: 10.1016/j.jss.2014.03.025

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  14 in total

1.  Gastroesophageal reflux disease after lung transplantation: pathophysiology and implications for treatment.

Authors:  Christopher S Davis; Vidya Shankaran; Elizabeth J Kovacs; James Gagermeier; Daniel Dilling; Charles G Alex; Robert B Love; James Sinacore; P Marco Fisichella
Journal:  Surgery       Date:  2010-08-21       Impact factor: 3.982

2.  Interpretative strategies for lung function tests.

Authors:  R Pellegrino; G Viegi; V Brusasco; R O Crapo; F Burgos; R Casaburi; A Coates; C P M van der Grinten; P Gustafsson; J Hankinson; R Jensen; D C Johnson; N MacIntyre; R McKay; M R Miller; D Navajas; O F Pedersen; J Wanger
Journal:  Eur Respir J       Date:  2005-11       Impact factor: 16.671

Review 3.  General considerations for lung function testing.

Authors:  M R Miller; R Crapo; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger
Journal:  Eur Respir J       Date:  2005-07       Impact factor: 16.671

4.  Twenty-four-hour pH monitoring of the distal esophagus. A quantitative measure of gastroesophageal reflux.

Authors:  L F Johnson; T R Demeester
Journal:  Am J Gastroenterol       Date:  1974-10       Impact factor: 10.864

5.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases.

Authors:  J A Hanley; B J McNeil
Journal:  Radiology       Date:  1983-09       Impact factor: 11.105

6.  Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension.

Authors:  Lionel Schachna; Thomas A Medsger; James H Dauber; Fredrick M Wigley; Neil A Braunstein; Barbara White; Virginia D Steen; John V Conte; Stephen C Yang; Kenneth R McCurry; Marvin C Borja; David E Plaskon; Jonathan B Orens; Allan C Gelber
Journal:  Arthritis Rheum       Date:  2006-12

7.  Laparoscopic fundoplication with or without pyloroplasty in patients with gastroesophageal reflux disease after lung transplantation: how I do it.

Authors:  Christopher S Davis; W Scott Jellish; P Marco Fisichella
Journal:  J Gastrointest Surg       Date:  2010-05-25       Impact factor: 3.452

8.  Outcomes of lung transplantation in patients with scleroderma.

Authors:  Malek G Massad; Charles R Powell; Jacques Kpodonu; Cimenga Tshibaka; Ziad Hanhan; Norman J Snow; Alexander S Geha
Journal:  World J Surg       Date:  2005-11       Impact factor: 3.352

9.  Lung transplantation in patients with connective tissue disorders and esophageal dysmotility.

Authors:  Warren J Gasper; Matthew P Sweet; Jeffrey A Golden; Charles Hoopes; Lorriana E Leard; Mary Ellen Kleinhenz; Steven R Hays; Marco G Patti
Journal:  Dis Esophagus       Date:  2008-05-02       Impact factor: 3.429

10.  Preoperative diagnostic workup before antireflux surgery: an evidence and experience-based consensus of the Esophageal Diagnostic Advisory Panel.

Authors:  Blair A Jobe; Joel E Richter; Toshitaka Hoppo; Jeffrey H Peters; Reginald Bell; William C Dengler; Kenneth DeVault; Ronnie Fass; C Prakash Gyawali; Peter J Kahrilas; Brian E Lacy; John E Pandolfino; Marco G Patti; Lee L Swanstrom; Ashwin A Kurian; Marcelo F Vela; Michael Vaezi; Tom R DeMeester
Journal:  J Am Coll Surg       Date:  2013-08-21       Impact factor: 6.113

View more
  8 in total

Review 1.  Evaluation of Gastroesophageal Reflux Disease.

Authors:  P Marco Fisichella; Ciro Andolfi; George Orthopoulos
Journal:  World J Surg       Date:  2017-07       Impact factor: 3.352

Review 2.  Advances in the evaluation and management of esophageal disease of systemic sclerosis.

Authors:  Dustin A Carlson; Monique Hinchcliff; John E Pandolfino
Journal:  Curr Rheumatol Rep       Date:  2015-01       Impact factor: 4.592

3.  Clinical Assessment of Gastrointestinal Involvement in Patients with Systemic Sclerosis.

Authors:  Timothy Kaniecki; Tsion Abdi; Zsuzsanna H McMahan
Journal:  Med Res Arch       Date:  2020-10-29

4.  Abnormal esophageal acid exposure on high-dose proton pump inhibitor therapy is common in systemic sclerosis patients.

Authors:  E K Stern; D A Carlson; S Falmagne; A D Hoffmann; M Carns; J E Pandolfino; M Hinchcliff; D M Brenner
Journal:  Neurogastroenterol Motil       Date:  2017-11-06       Impact factor: 3.598

Review 5.  Management of Systemic-Sclerosis-Associated Interstitial Lung Disease.

Authors:  Katherine Culp Silver; Richard M Silver
Journal:  Rheum Dis Clin North Am       Date:  2015-05-23       Impact factor: 2.670

Review 6.  Evaluation and management of esophageal manifestations in systemic sclerosis.

Authors:  Konstantinos Denaxas; Spyros D Ladas; George P Karamanolis
Journal:  Ann Gastroenterol       Date:  2018-01-18

Review 7.  Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review.

Authors:  Caterina Vacchi; Marco Sebastiani; Giulia Cassone; Stefania Cerri; Giovanni Della Casa; Carlo Salvarani; Andreina Manfredi
Journal:  J Clin Med       Date:  2020-02-03       Impact factor: 4.241

8.  Clinical spectrum and presentation of patients with absent contractility.

Authors:  Balazs Kovacs; Takahiro Masuda; Ross M Bremner; Sumeet K Mittal
Journal:  Ann Gastroenterol       Date:  2021-01-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.